DPT

Across TCGA pan-cancer cohorts, DPT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPT data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DPT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DPT expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where DPT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.692	0.451	.003	17	view →
LSCC	DFS	Tertile	II,III,IV	0.794	1.000	.005	13	view →
LUAD	OS	Quartile	III,IV	0.197	1.000	.010	10	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	8	view →
CCRCC	DFS	Median	II,III,IV	0.199	0.839	.011	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPT–PDAC (OS)

Open the PDAC breakdown →